Boehringer In­gel­heim adds sec­ond AI part­ner in a month

6 years ago
Deals
AI

A risky bet on a long-de­layed CAR-T drug now faces a do-or-die dead­line — where any slip can kill a $9 CVR

6 years ago
R&D
FDA+

Roche flash­es new 16-week bis­pe­cif­ic AMD da­ta, set­ting eyes on pair of PhI­II tri­als

6 years ago
R&D

Af­ter big 2016 set­back, field of mi­cro­bio­me-based drugs gets in­jec­tion of promise with pos­i­tive sig­nal from Re­bi­otix ...

6 years ago
R&D

'It's pure art': Ver­sant, GV re­veal $60M bet that a clear­er look at in­flam­ma­somes can lead to bet­ter drugs

6 years ago
Financing
Startups

Ab­b­Vie gets the FTC's di­vid­ed bless­ing for its $63B Al­ler­gan buy­out — free­ing Brent Saun­ders to blaze a new path

6 years ago
People
Deals

Covid-19 roundup: Epi­demi­ol­o­gist cred­it­ed for shap­ing UK pol­i­cy vi­o­lates lock­down mea­sures; Here's Gilead’s glob­al ...

6 years ago
Coronavirus

Oust­ed BAR­DA chief Rick Bright blasts HHS of­fi­cial for a long record of im­prop­er in­ter­fer­ence that pre­ced­ed the ...

6 years ago
People
R&D

Ad­verum soars on ear­ly gene ther­a­py da­ta; BerGen­Bio rais­es €45.4M on the heels of Covid-19 move

6 years ago
News Briefing

Ake­bia touts da­ta for two PhI­II stud­ies, set­ting up show­down with As­traZeneca, Fi­bro­Gen

6 years ago
R&D

Two years af­ter U2 dis­ap­point­ment, TG Ther­a­peu­tics wins back in­vestors with PFS win — set­ting the stage for NDA

6 years ago
R&D

Bil­lions for biotech: Ober­land boosts biotech fund-rais­ing past the $5B mark in a mat­ter of weeks

6 years ago
Financing

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to ...

6 years ago
Deals

A UCSD cen­ter that's been fa­cil­i­tat­ing Covid-19 clin­i­cal re­search gets $55M from NIH to boost trans­la­tion­al work

6 years ago
R&D
Discovery

Alex­ion bags a dis­count biotech buy­out for $1.4B, branch­ing out in new di­rec­tions from its Soliris fran­chise

6 years ago
Deals

Covid-19 roundup: Pfiz­er, BioN­Tech start US hu­man tri­al; World lead­ers (not in­clud­ing the US) pledge $8 bil­lion in ...

6 years ago
Coronavirus

Prax­is Pre­ci­sion Med­i­cines launch­es with $100M and bold sights on long-eva­sive neu­ro­log­i­cal dis­or­ders

6 years ago
Financing
Startups

Bat­tling low ex­pec­ta­tions and go­liath ri­vals, Re­gen­eron/Sanofi add pos­i­tive Lib­tayo da­ta in pur­suit of block­buster ...

6 years ago
R&D
FDA+

With the pric­ing ball in Gilead’s court, ICER of­fers some pa­ra­me­ters on how it can be played — an­a­lyst sees at ...

6 years ago
Coronavirus

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

6 years ago
R&D
Coronavirus

FDA cre­ates um­brel­la emer­gency path­way for Covid-19 serol­o­gy tests

6 years ago
FDA+
Coronavirus

Bio­Marin broad­ens its gene ther­a­py hori­zons with a new R&D al­liance in rare car­dio cas­es

6 years ago
Deals
R&D

New Darza­lex for­mu­la­tion wins FDA ap­proval; Is­raeli biotech plans $50M IPO

6 years ago
News Briefing

Menar­i­ni bags Stem­line and a rare dis­ease drug in $677M buy­out. But will a bet­ter of­fer fol­low?

6 years ago
Deals
First page Previous page 830831832833834835836 Next page Last page
A service from the Financial Times